INTRODUCTION: Testicular cancer affects men mostly in their reproductive age with a cure rate over 90% and fertility is one of the main concerns of survivors. To further elucidate the question of fertility after treatment for testicular cancer, we performed a survey in patients treated in our institution. PATIENTS AND METHODS: We sent a questionnaire to patients treated for testicular cancer at our institute from 1976 to 2002 (n = 490) of whom 297 (60.6%) responded. We considered the patients to have conserved fertility if they had children after treatment without assisted reproductive technologies. RESULTS: Before treatment 119/297 (40.1%) of patients and after treatment 150/297 (50.5%) of patients tried to have children (p = 0.019). Of 119 patients who tried to have children before treatment for testicular cancer 98 (82.4%) succeeded and 74/150 (49.3%) were successful after treatment (p < 0.001). After treatment patients had 1-3 (median 1) children. The median time to birth of first child from diagnosis was 12 years. The post-treatment fatherhood in patients treated with surgery only (orchidectomy +/- retroperitoneal lymphnode dissection-RPLND) was 59%, in those with additional radiotherapy 68%, and chemotherapy 50% (p = 0.233). Fertility rate in patients where a non nerve sparing RPLND was performed was only 37%, 62% in patients with nerve sapring RPLND, and 77% in patients where RPLND was not performed (p < 0.0001). CONCLUSION: Fertility rate after treatment for testicular cancer is reduced. From our data, the most important treatment modality that influences fertility is non nerve sparing RPLND that should be avoided whenever possible in order improve the quality of life our patients.
INTRODUCTION:Testicular cancer affects men mostly in their reproductive age with a cure rate over 90% and fertility is one of the main concerns of survivors. To further elucidate the question of fertility after treatment for testicular cancer, we performed a survey in patients treated in our institution. PATIENTS AND METHODS: We sent a questionnaire to patients treated for testicular cancer at our institute from 1976 to 2002 (n = 490) of whom 297 (60.6%) responded. We considered the patients to have conserved fertility if they had children after treatment without assisted reproductive technologies. RESULTS: Before treatment 119/297 (40.1%) of patients and after treatment 150/297 (50.5%) of patients tried to have children (p = 0.019). Of 119 patients who tried to have children before treatment for testicular cancer 98 (82.4%) succeeded and 74/150 (49.3%) were successful after treatment (p < 0.001). After treatment patients had 1-3 (median 1) children. The median time to birth of first child from diagnosis was 12 years. The post-treatment fatherhood in patients treated with surgery only (orchidectomy +/- retroperitoneal lymphnode dissection-RPLND) was 59%, in those with additional radiotherapy 68%, and chemotherapy 50% (p = 0.233). Fertility rate in patients where a non nerve sparing RPLND was performed was only 37%, 62% in patients with nerve sapring RPLND, and 77% in patients where RPLND was not performed (p < 0.0001). CONCLUSION: Fertility rate after treatment for testicular cancer is reduced. From our data, the most important treatment modality that influences fertility is non nerve sparing RPLND that should be avoided whenever possible in order improve the quality of life our patients.
Authors: Noa Shani Shrem; Lori Wood; Robert J Hamilton; Kopika Kuhathaas; Piotr Czaykowski; Matthew Roberts; Andrew Matthew; Jason P Izard; Peter Chung; Lucia Nappi; Jennifer Jones; Denis Soulières; Armen Aprikian; Nicholas Power; Christina Canil Journal: Can Urol Assoc J Date: 2022-08 Impact factor: 2.052
Authors: Bernhard Holzner; Fabio Efficace; Umberto Basso; Colin D Johnson; Neil K Aaronson; Juan I Arraras; Allan B Smith; Edward Chow; Anne S Oberguggenberger; Andrew Bottomley; Hannes Steiner; Luca Incrocci; Johannes M Giesinger Journal: Qual Life Res Date: 2012-03-10 Impact factor: 4.147
Authors: M Brydøy; S D Fosså; O Klepp; R M Bremnes; E A Wist; T Bjøro; T Wentzel-Larsen; O Dahl Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640